Open company graph database — free web & API
Login

SS Pharmaceutical Co., Ltd.

エスエス製薬エスエス製薬株式会社AliasSSP CO., LTD.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
2
§01

Basic information

BASIC
Head office
3-20-2 Nishi-Shinjuku, Shinjuku-ku, Tokyo
Chief executive
Capital
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

43
Cialis® (over-the-counter ED medicine)SourcesEstac Vita Force (cold medicine)SourcesNESUGI (pollen relief medicine)SourcesイブSourcesSourcesアレジオンSourcesSourcesハイチオールSourcesSourcesドリエルSourcesSourcesエスタックSourcesSourcesシアリス®SourcesSourcesスルーラックSourcesSourcesガストールSourcesSourcesアネロンSourcesSourcesアレグラFXプレミアムSourcesSourcesSleep aidSourcesSourcesFoods with Function ClaimsSourcesDesignated Class 2 OTC medicineSourcesDrewell Your Rhythm DeepSourcesDrewell Your Rhythm RelaxSourcesDrewell Your Rhythm BeautySourcesDrewell Natural SleepSourcesDrewell Natural Sleep αSourcesAntipyretic analgesicsSourcesAllergy medications for rhinitisSourcesL-cysteine and vitamin-related productsSourcesCold remediesSourcesED medicationsSourcesLaxatives, etc.SourcesGastrointestinal medicationsSourcesMotion sickness medicationsSourcesCough suppressants and expectorantsSourcesBronSourcesWakefulness-promoting medicationsSourcesEstalon MochaSourcesBuscopanSourcesVitamin B supplementsSourcesS-Fight GoldSourcesTopical medicationsSourcesMemo ASourcesAnna Salve AceSourcesStomachics and refreshing agentsSourcesSS Gastrointestinal GranulesSourcesPharmaceutical Ingredient DictionarySourcesRetailer SearchSources
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Opella Sources
Group
オペラグループ Sources
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

33 EVENTS

In 1889, the national pharmacy law established pharmacies and drugstores nationwide, and the sales network of this pharmacy expanded to local areas by entering into wholesale agreements and exclusive contracts with wholesalers.Sources

During the Taishō era that began in 1912, the efforts of the sixth president, Masakazu, were realized. The manufacturing base was relocated to Ebara in Tokyo (now Shinagawa Ward), and the company developed and manufactured both traditional Japanese and Western chemical drugs. A nationwide sales network was also established, and significant achievements began to be realized.Sources

On October 29, 1927, the company was incorporated as "Hyo Taneya Pharmacy Co., Ltd." At that time, the company produced almost all of the popular over‑the‑counter drugs, and continued to produce products such as "Ninjin Ume Kō" that had been loved for 170 years since its Edo‑era founding.Sources

In 1940, the company name was changed to the current trade name "SS Pharmaceutical." The president at that time was the sixth president, Masakazu Shirai.Sources

In 1945, the Ebara factory was destroyed by air raids. Production was completely lost, and the company’s activities were halted until the end of the war.Sources

On August 15, 1945, Japan surrendered unconditionally to the Allies. The Second World War ended, but the damage was severe: all production facilities and buildings were destroyed, and the company’s operations were suspended.Sources

On the early morning of August 16, 1945, the company’s employees began reconstruction on the site of the former Ebara factory.Sources

In December 1951, the company moved its headquarters from its long‑standing founding location in Yae‑su (now part of Chiyoda) to a newly built building in Ginza. The Osaka branch was also relocated and rebuilt at the same time.Sources

In 1952, the "rabbit mark" was adopted as the unified logo for the SS chain. It began to be used as the brand mark for SS products and the company emblem.Sources

In February 1958, a financial miscalculation led to a downturn in management, causing the then‑president, the sixth Masakazu Shirai, to step down. Tode Moriyoshi became president.Sources

In 1963, the headquarters moved from Ginza to the front of Suiten‑gū in Nihonbashi. Construction of the Narita factory also began.Sources

In 1964, the year of the Tokyo Olympics, the long‑awaited Narita factory completed its first phase of construction and began operations immediately, becoming the central hub of the company’s production activities.Sources

In 1965, a new Osaka branch building was constructed to support nationwide sales expansion, and in November a new headquarters building was completed in Nihonbashi Hamacho.Sources

In May 1972, the company launched a new L‑cysteine formulation, "Highi‑Tōru C."Sources

May 1972 – Birth of Haitiol CSources

In 1985, the company released its second OTC pain reliever, "Ibuprofen," converting a medical drug into an OTC product, and SS Pharmaceutical’s development capabilities were highly praised.Sources

In 1988, the company entered a capital and technology partnership with the American company Iba‑X, strengthening its development capabilities and establishing overseas bases.Sources

In 1989, as Japan transitioned from the Showa to the Heisei era, the pharmaceutical industry had to consider global scale operations. The company continued its overseas expansion by partnering with the German company NUTRIKEM and investing in the Korean company Haedong Pharmaceutical, focusing on establishing overseas bases.Sources

In 1997 (Heisei 9), Bayer Ingelheim Japan became the company's largest shareholder with a 9.2% stake.Sources

In 1997 (Heisei 9), on the occasion of the company's 70th anniversary, a new corporate philosophy was adopted: "We wish for the health of all people, continue limitless exploration and challenge, and aim to be a trusted and beloved healthcare provider."Sources

July 1998 – Renewal of Haitiol CSources

In August 1998 (Heisei 10), the Narita plant obtained ISO 14001 certification for its environmental management system.Sources

In 2001 (Heisei 13), Bayer Ingelheim Japan's ownership exceeded 50%, and SS Pharmaceutical became part of Bayer Ingelheim.Sources

In 2003 (Heisei 15), the company released a series of new products, including the new OTC drug "New Switch."Sources

In 2005 (Heisei 17), the company divested its pharmaceutical business and was reborn as a company focused on consumer healthcare.Sources

March 2006 – Release of Haitiol C PremierSources

In 2010 (Heisei 22), SS Pharmaceutical became a wholly-owned subsidiary of Bayer Ingelheim, enabling further synergy in new product development, talent development, and marketing, distribution, and sales strategy.Sources

In 2011 (Heisei 23), the new structure of Bayer Ingelheim Japan Group began. Under Bayer Ingelheim Japan Co., Ltd., the domestic group companies share the same values and aim to grow together.Sources

In the same year, "Alezion 10" was launched. It was the first OTC medication in Japan to contain the Bayer Ingelheim-developed active ingredient epinastine hydrochloride. With high efficacy, low drowsiness, and a once‑daily dosage of one tablet, it differentiated itself and significantly contributed to consumers' self‑medication.Sources

In March of the same year, the Great East Japan Earthquake damaged the factory, but management and employees united to support the affected areas and employees. Additional support from the entire Bayer Ingelheim Group helped overcome the crisis.Sources

In January 2017 (Heisei 29), the exchange of Sanofi's animal health business with Bayer Ingelheim's consumer healthcare (CHC) business was completed, making SS Pharmaceutical a member of the Sanofi Japan Group as of January 1 of that year.Sources

In December of the same year, the headquarters moved from Nihonbashi Hamacho to the same Tokyo Opera City Tower as Sanofi Japan, aiming to create further synergy as part of Sanofi Japan Group's CHC business.Sources

In April 2025, SS Pharmaceutical completed the spin‑off of the global company Opella. (Opella), and under the new structure, it began operating. SS Pharmaceutical, a former subsidiary of French pharmaceutical company Sanofi, became a 100% subsidiary of the Opella Group, which operates in self‑care across more than 100 countries.Sources

§07

News

37 ARTICLES

Transfer of Allegra Manufacturing and Sales Approval and Change of Sales StructureSources

SS Pharmaceutical received the transfer of manufacturing and sales approval for "Allegra FX", "Allegra FX Junior", and "Allegra FX Premium" from Sanofi on November 2. From that date, sales of "Allegra FX" and "Allegra FX Junior" began, and "Allegra FX Premium" will continue to be sold. The company will strive to ensure stable supply as the manufacturer and will continue to provide information to relevant institutions and promote appropriate use.

New Estac Commercial Featuring Kento Kaku to Air NationwideSources

Estac, SS Pharmaceutical’s comprehensive cold medicine brand, will air a new 15-second TV commercial titled “The Strength to Bounce Back. Estac” featuring Kento Kaku nationwide (excluding some areas) from October 26, 2026. The commercial introduces Estac EX Neo, which is effective against all 11 cold symptoms, and Estac Vita Force, launched in September 2026. Thirty-second commercials highlighting the features of each product will also be released and distributed in stages on the brand website, the official YouTube channel, and through digital advertising.

SS Pharmaceutical Begins Selling Cialis® on Amazon.co.jpSources

SS Pharmaceutical Co., Ltd. has begun online sales of Cialis®, an over-the-counter medicine for erectile dysfunction, on Amazon.co.jp. Starting October 20, 2026, customers can safely access genuine products, with a system in place that allows them to purchase after consulting a pharmacist.

Pillow Mist “NESUGI” Wins the 2026 Good Design AwardSources

Pillow mist “NESUGI,” whose development was supported by SSP, won the 2026 Good Design Award. It was recognized for creating a pleasant sleep environment with a fragrance made from pollen-producing cedar trees and for contributing to a fundamental solution to the pollen problem by promoting the use of cedar.

SS Pharmaceutical Recertified as a B Corp Under B Lab’s New StandardsSources

SS Pharmaceutical Co., Ltd. (headquartered in Shinjuku, Tokyo) has obtained B Corp™ recertification under B Lab’s New Standards V2, with Opera responsible for its business in Japan. This recertification further strengthens the leadership of its initial B Corp certification, which it obtained in April 2025.

Estac Vita Force, a Combination Cold Medicine Containing Vitamins C and B1, Launches on September 8Sources

SS Pharmaceutical began selling Estac Vita Force, a combination cold medicine containing five active ingredients plus vitamins C and B1, on September 8. The product is formulated to relieve all 11 cold symptoms and support recovery from a cold.

Donation for the 2026 Kumamoto EarthquakeSources

SS Pharmaceutical has decided to donate 5 million yen to the Japanese Red Cross Society to support relief efforts for those affected and recovery in the disaster-stricken areas.

SS Pharmaceutical to Begin Nationwide Launch of Cialis®, Japan’s First Over-the-Counter ED MedicationSources

SS Pharmaceutical Co., Ltd. will begin nationwide sales of Cialis®, Japan’s first over-the-counter medication for erectile dysfunction (ED), on August 31, 2026. At participating stores with pharmacists on staff, the company will establish a sales system that supports access to authentic products and raise awareness of ED as a health issue that can be addressed.

SSP Co., Ltd. and Morinaga & Co., Ltd. Launch Cross-Mentoring Program to Support Women's CareersSources

As part of the BeliEVE PROJECT, SSP Co., Ltd. is partnering with Morinaga & Co., Ltd. to implement a mentoring program aimed at supporting the careers of female employees. The two companies share common values in the fields of pharmaceuticals and food, and aim to broaden career perspectives through opportunities for dialogue across company lines.

SS Pharmaceutical Begins Selling Cialis® as Japan’s First Over-the-Counter ED DrugSources

SS Pharmaceutical Co., Ltd. will start selling Cialis® at selected stores staffed by pharmacists from July 31, 2026, and plans to roll out nationwide from August 31. The OTC availability will create an environment where people struggling with ED can receive appropriate care under pharmacist guidance.

§08

Public records

GOV
National Tax Agency basic information8010001034749
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
エスエス製薬株式会社
Trade name (kana)
エスエスセイヤク
Name in English
Corporation type
301
Address
〒160-0023 東京都新宿区西新宿3丁目20番2号
Postal code
1600023
Prefecture code
13
City code
104
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-18
Change date
2018-03-07
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2313309
METI gBizINFO8010001034749
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8010001034749
Trade name
エスエス製薬株式会社
Trade name (kana)
エスエスセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都新宿区西新宿3丁目20番2号
Postal code
1600023
Prefecture
東京都
Prefecture code
13
City or district
新宿区
City code
104
Street address
西新宿3丁目20番2号
Organisation type
301
Processing type
12
Correction type
1
Status
Representative
Capital
Employees
441
Employees (male)
Employees (female)
Business summary
医薬品、医薬部外品、化粧品、食品等の製造・販売
Website URL
http://www.ssp.co.jp/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-04-18
Key information
8010001034749
§09

Sources & updates

SOURCES
↑